BioAlliance Pharma accelerates its European clinical development of clonidine Lauriad
Based on the incidence of chemoradiation therapy induced oral mucositis in this population, BioAlliance Pharma plans to submit an application dossier to the European and US agencies in Q2 2011 to obtain an Orphan Drug designation for clonidine Lauriad™.
"The orphan drug designation will qualify clonidine Lauriad™ for our "Orphan Oncology" Business Unit, which features breakthrough products for severe and rare cancers. In addition to clonidine Lauriad™, this Unit covers various projects including, at clinical stage, Livatag® (advanced hepatocellular carcinoma) in phase II and the AMEP® biotherapy (invasive metastatic melanoma) in phase I", comments Judith Greciet, Chief Operating Officer, Operations and R&D of BioAlliance Pharma.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.